SARS-CoV-2 main protease (Mpro) is a cysteine protease playing a pivotal role in virus replication, therefore representing a highly attractive target for the development of broad-spectrum anti-coronavirus therapies due to its high degree of conservation across coronaviruses. Mpro functions as a homodimer, with each protomer comprising 306 amino acids, including 12 reduced cysteines (Cys). Among various compounds screened as potential inhibitors, Ebselen emerged as a leading candidate from a drug repurposing campaign, exhibiting a nanomolar range potency. This organoselenium small molecule reacts with cysteines thiols, forming a S-Se covalent bond. Although in the scientific community is well established that Mpro inhibition results from Ebselen binding to the catalytic cysteine Cys145, recent mass spectrometry-based studies showed how this compound and its derivatives are capable of inducing a dose-dependent shift in the monomer-dimer equilibrium toward the inactive form represented by the monomer. These observations suggest how additional cysteine, particularly Cys300, located at the dimerization interface, and Cys44, could be involved in the viral enzyme loss of activity upon Ebselen binding. The aim of this study is to further elucidate the inhibition mechanism of Ebselen (and its derivatives) by mapping Ebselen preferential binding sites among Mpro’s 12 cysteines. To achieve this a bottom-up analysis approach based on chromatographic separation directly couplet with tandem mass spectrometry mode of acquisition, has been developed to study the complex peptide mixture obtained by the trypsin digestion of Mpro. In parallel, in vitro testing via mass spectrometry, under both denaturing (ESI) and native (nESI-MS) conditions, and biochemical assays on a set of Ebselen derivative have been conducted to build a structure-activity-relationship (SAR) capable of correlating the presence of electron-donating/withdrawing substituent on the benzoselenazolone scaffold and on the acyl group with the inhibitory potency of the compound.
SARS-CoV-2 Main Protease (Mpro) rappresenta un promettente bersaglio terapeutico per lo sviluppo di antivirali per via del suo ruolo chiave nel ciclo di replicazione virale, l’assenza di omologhi umani e l’alto grado di conservazione tra i coronavirus. Mpro è una cistein-proteasi attiva come omodimero, con ciascun protomero composto da 306 amminoacidi, di cui 12 cisteine (Cys). Tra i diversi composti testati come potenziali inibitori, Ebselen è risultato un promettente candidato da studi di reporpousing, esibendo una potenza inibitoria nell’ordine del nanomolare. Questo composto organoselenico reagisce con i tioli delle cisteine formando un legame covalente S-Se. Per anni la comunità scientifica internazionale ha interpretato la perdita di attività della proteasi virale con il legame di Ebselen alla cisteina catalitica (Cys145) ma recenti studi basati sulla spettrometria di massa hanno dimostrato come questo composto, e i suoi derivati, inducano uno shift dose-dipendente dell’equilibrio monomero-dimero verso la forma inattiva, rappresentata dal monomero. Questa evidenza suggerisce come altre cisteine, in particolare Cys300, posta all’interfaccia di dimerizzazione, e Cys44, possano essere implicate nella perdita di attività della proteasi a seguito del legame da parte di Ebselen. Lo scopo di questo lavoro consiste nell’elucidazione del meccanismo d’azione di Ebselen (e dei suoi derivati) attraverso l’identificazione dei siti preferenziali di legame tra le 12 cisteine di Mpro. A tale scopo è stato sviluppato un protocollo di analisi bottom-up, basato sulla separazione cromatografica accoppiata a spettrometria di massa tandem (LC-MS/MS) per lo studio dei peptidi ottenuti attraverso digestione triptica di Mpro. In parallelo è stata testata una ridotta libreria di derivati bi-sostituiti di Ebselen mediante saggi biochimici in vitro e analisi di spettrometria di massa, in condizioni denaturanti (ESI-MS) e native (nMS), al fine di costruire una relazione struttura-attività (SAR) capace di correlare l’introduzione di diversi gruppi sostituenti allo scaffold di Ebselen con la sua reattività e la capacità inibitoria.
Elucidazione del meccanismo di inibizione della dimerizzazione di SARS-CoV-2 Main Protease (Mpro) da parte di Ebselen e derivati
CALORE, ANDREA
2025/2026
Abstract
SARS-CoV-2 main protease (Mpro) is a cysteine protease playing a pivotal role in virus replication, therefore representing a highly attractive target for the development of broad-spectrum anti-coronavirus therapies due to its high degree of conservation across coronaviruses. Mpro functions as a homodimer, with each protomer comprising 306 amino acids, including 12 reduced cysteines (Cys). Among various compounds screened as potential inhibitors, Ebselen emerged as a leading candidate from a drug repurposing campaign, exhibiting a nanomolar range potency. This organoselenium small molecule reacts with cysteines thiols, forming a S-Se covalent bond. Although in the scientific community is well established that Mpro inhibition results from Ebselen binding to the catalytic cysteine Cys145, recent mass spectrometry-based studies showed how this compound and its derivatives are capable of inducing a dose-dependent shift in the monomer-dimer equilibrium toward the inactive form represented by the monomer. These observations suggest how additional cysteine, particularly Cys300, located at the dimerization interface, and Cys44, could be involved in the viral enzyme loss of activity upon Ebselen binding. The aim of this study is to further elucidate the inhibition mechanism of Ebselen (and its derivatives) by mapping Ebselen preferential binding sites among Mpro’s 12 cysteines. To achieve this a bottom-up analysis approach based on chromatographic separation directly couplet with tandem mass spectrometry mode of acquisition, has been developed to study the complex peptide mixture obtained by the trypsin digestion of Mpro. In parallel, in vitro testing via mass spectrometry, under both denaturing (ESI) and native (nESI-MS) conditions, and biochemical assays on a set of Ebselen derivative have been conducted to build a structure-activity-relationship (SAR) capable of correlating the presence of electron-donating/withdrawing substituent on the benzoselenazolone scaffold and on the acyl group with the inhibitory potency of the compound.| File | Dimensione | Formato | |
|---|---|---|---|
|
Calore_Andrea.pdf
Accesso riservato
Dimensione
4.43 MB
Formato
Adobe PDF
|
4.43 MB | Adobe PDF |
The text of this website © Università degli studi di Padova. Full Text are published under a non-exclusive license. Metadata are under a CC0 License
https://hdl.handle.net/20.500.12608/118512